K223826 is an FDA 510(k) clearance for the NanoDrop Lancet. Classified as Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature (product code FMK), Class II - Special Controls.
Submitted by Drawbridge Health, Inc. (Summerville, US). The FDA issued a Cleared decision on February 22, 2024 after a review of 428 days - an unusually long review period, suggesting complex equivalence evaluation.
This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4850 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind General & Plastic Surgery submissions.
View all Drawbridge Health, Inc. devices